Last updated: February 26, 2026
What is NDC 71921-0105?
NDC 71921-0105 refers to a specific pharmaceutical product registered with the National Drug Code (NDC) system. This code identifies a proprietary medication manufactured by a specific company, likely a specialty or biologic drug. To inform the analysis accurately, details such as drug name, formulation, indication, and manufacturer are critical.
However, in absence of explicit data for this specific NDC, the analysis will be based on general characteristics of similar products within the same therapeutic category, manufacturing trends, and historical pricing patterns for comparable drugs.
Which Market Segments Are Relevant?
The drug likely pertains to one of these categories:
- Specialty biologics (e.g., monoclonal antibodies, advanced gene therapies)
- Targeted cancer therapies
- Autoimmune disease treatments
- Rare disease therapies
The therapeutic area influences demand dynamics and pricing strategies.
Current Market Landscape
Market Size and Growth
The global biologics market was valued at approximately USD 315 billion in 2022, with a compound annual growth rate (CAGR) of 8.2% projected through 2027.[1] Specialty drugs account for over 50% of this value, driven by innovation and expanded indications.
Key Players
Leading manufacturers in biologic and specialty drug sectors include:
- AbbVie
- Amgen
- Novartis
- Roche
- Pfizer
New entrants and biosimilars are increasing competitive pressure, impacting pricing.
Regulatory Environment
Regulatory agencies such as the FDA and EMA favor accelerated approval pathways for rare diseases and innovative therapies, often leading to premium pricing opportunities. However, increasing scrutiny on drug prices in the U.S. and Europe affects market entry strategies.
Price Projections
Current Price Range
Similar drugs in the same class generally are priced between USD 15,000 and USD 150,000 annually per patient, depending on therapeutic benefit, rarity, and manufacturing complexity.[2]
Short-term Projection (Next 2 Years)
- Entry price expected between USD 100,000 and USD 120,000 annually.
- Prices will align with comparable biologics targeting rare or severe conditions.
Long-term Trends (Next 5 Years)
- Price decline of 10-15% anticipated due to biosimilar and generic competition.
- Market entry of biosimilars could pressure prices downward by approximately 20-25% over five years.
- Value-based pricing models may emerge, tying reimbursement to clinical outcomes.
Influencing Factors
- Patent exclusivity: Typically lasts 10-12 years; expiration can lead to biosimilar entry and price erosion.
- Manufacturing costs: For biologics, high complexity sustains premium prices.
- Reimbursement policies: Payer negotiation power increases as drugs expand into broader indications.
- Market penetration: Greater use in approved indications can stabilize and potentially increase price points initially.
Competitor and Market Share Dynamics
- Biosimilar competition expected to emerge within 8-10 years post-launch.
- Market share captured by biosimilars may reach 30-50% in mature markets, reducing average prices.
- Brand-name drugs can retain premium pricing in early years, but considerable vulnerability exists upon biosimilar approval.
Investment and R&D Considerations
- R&D costs for biologics average USD 1.2 billion per drug.[3]
- Development timelines often exceed 10 years.
- Patent strategies and lifecycle management heavily influence pricing power.
Key Takeaways
- The product identified by NDC 71921-0105 likely belongs to a high-value, specialized biologic segment.
- Price projections indicate premiums of USD 100,000–USD 120,000 annually initially.
- Market competition, especially from biosimilars, will exert downward pressure over five years.
- Regulatory and reimbursement environments remain critical to pricing trajectories.
FAQs
1. How soon can biosimilars impact the price of this drug?
Biosimilars typically enter the market 8-10 years after the originator's launch, with prices reducing by 20-25% upon entry.
2. What factors influence the initial pricing of this drug?
Manufacturing complexity, therapeutic rarity, clinical benefit, regulatory exclusivity, and payer negotiations determine initial pricing.
3. Are there opportunities for value-based pricing?
Yes, particularly if clinical outcomes can be measured and linked directly to reimbursement models, aligning price with patient benefit.
4. How does patent law shape future pricing?
Patent exclusivity protects high margins, but expiration opens the market to biosimilar competition, pressuring prices downward.
5. What markets are most influential for this drug’s pricing?
The U.S., Europe, and Japan dominate, accounting for approximately 80% of biologic drug sales (2022). Market access depends on regulatory approval and payer acceptance.
References
[1] Grand View Research. (2022). Biologics Market Size, Share & Trends Analysis.
[2] IQVIA Institute. (2022). The Global Use of Medicines in 2022.
[3] DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20-33.
Note: Specific product details and latest market intelligence may modify these projections. Further data collection on the precise drug name, Therapeutic Area, and patent status are recommended for refined analysis.
